VALIDATE: Factor VIII Trending for MS Relapse

VALIDATE: Factor VIII Trending for MS Relapse

Publication date: Sep 09, 2019

Multiple sclerosis (MS) patients hospitalized with an acute motor or visual relapse will be consented. Factor VIII-related labs will be systematically drawn for six months. During this time, patients will be followed with clinical assessments including: Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), Low Contrast Sloan Letter Chart Testing, Symbol Digital Modality Test (SDMT), and NeuroQol. MRIs of the brain, cervical spine, and thoracic spine with and without contrast will be obtained. All patients will be treated with 1 gram IV solumedrol daily for five days per standard care. Clinical, imaging, and Factor VIII-related lab data individually or in aggregate will be correlated with relapse presence, severity, and extent of recovery following standard intravenous (IV) solumedrol treatment

Concepts Keywords
Ambulation Tests assistive devices
Antigen Imaging
Arizona MS
Assistive Devices Stroke tumor
Blood Multiple sclerosis
Brain Medicine
Cervical Spine Organ systems
Clinical Trial Clinical medicine
Coagulation Relapsing–remitting
Cognitive Function EDSS
Coumadin Multiple sclerosis research
Dabigatran MRI
Factor VIII
Glucocorticoid
Gram
Heparin
Hospital
Intravenous
Modality
MRI
Multiple Sclerosis
Neurological
Phoenix
Plasma
Relapse
Rivaroxaban
Solumedrol
Stroke
Test
Thoracic Spine
Tumor
Von Willebrand Factor
Warfarin
Xarelto

Semantics

Type Source Name
drug DRUGBANK Beroctocog alfa
disease MESH Relapse
disease MESH Multiple sclerosis
disease DOID Multiple sclerosis
disease MESH visual
gene UNIPROT LAT2
disease MESH diagnosis
disease MESH relapsing remitting multiple sclerosis
disease DOID RRMS
gene UNIPROT CYREN
drug DRUGBANK Heparin
drug DRUGBANK Warfarin
drug DRUGBANK Dabigatran
drug DRUGBANK Rivaroxaban
disease MESH stroke
disease DOID stroke
disease MESH tumor

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *